Afshin Eli Gabayan

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results

Alexander M. Lesokhin, Michael H. Tomasson, Bertrand Arnulf et al. · Nature Medicine · 2023 · 564 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Extended follow‐up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma

Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf et al. · British Journal of Haematology · 2009 · 56 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Abdominal Tuberculosis in Patients Infected with the Human Immunodeficiency Virus

M. J. Fee, Maung Maung Oo, Afshin Eli Gabayan et al. · Clinical Infectious Diseases · 1995 · 49 citations

Life Sciences, Infectious Diseases, Microbiology +15

A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus <i>nab</i>-Paclitaxel and Gemcitabine in Advanced Solid Tumors

Gregory L. Beatty, Safi Shahda, Thaddeus Beck et al. · The Oncologist · 2018 · 47 citations · Full text

Medicine, Oncology, Pharmacology +16

Long-Term Follow-Up of Patients Treated with Bortezomib Alone and in Combination with Dexamethasone as Frontline Therapy for Multiple Myeloma.

Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf et al. · Blood · 2006 · 39 citations

Medicine, Hematology, Pharmacotherapy +12